Arovella Therapeutics Ltd (ASX:ALA) moved higher during the afternoon session on 7 May 2026, rising 5.63% to A$0.075, as investors responded positively to the Company’s latest Leadership update. The gain followed Arovella’s announcement that Dr Nicole Van Der Weerden had been appointed Acting Chief Executive Officer, marking the next step in the Company’s evolving governance transition and helping extend market focus beyond the Board departures disclosed earlier in the week.

The latest announcement effectively builds on the governance reshuffle that emerged after four directors, including former CEO Dr Michael Baker, ceased their roles on 4 May 2026. While the earlier Appendix 3Z disclosures primarily documented the formal cessation of directors and their security interests, today’s update provided the market with a clearer operational direction by confirming an immediate leadership structure and signalling continuity ahead of Arovella’s planned Phase I clinical program for ALA-101.

Investors appeared encouraged by the Company’s decision to elevate an existing senior executive with deep biotechnology and clinical development experience rather than leaving uncertainty around executive leadership unresolved. The appointment of Dr Van Der Weerden, who previously served as Chief Operating Officer and held senior leadership positions at Hexima Ltd, may also be viewed as an attempt to stabilise execution as Arovella advances its CAR-iNKT cell therapy platform toward clinical-stage milestones.

Arovella Therapeutics (ASX:ALA) Confirms Departure of Four Directors with Final Appendix 3Z Notices

Clinical-stage biotechnology company Arovella Therapeutics Limited (ASX: ALA) has lodged Appendix 3Z Final Director's Interest Notices in respect of four directors who ceased to be members of the Board on 4 May 2026. The departures, formalised in disclosures dated 7 May 2026, cover Andrew Nash, Debora Barton, Michael Baker and Michael Steven Perry. The notices set out the relevant directors' interests in Arovella securities at the time of their cessation.

While individual Appendix 3Z notices are administrative in nature, the simultaneous lodgement of four such notices on the same date represents a meaningful Board-level event for any listed company. For shareholders evaluating Arovella's governance and leadership trajectory, the disclosures provide a structured record of the changes that have occurred and the resulting Board interest profile.

Why This Announcement Matters

Final Director's Interest Notices are required under ASX Listing Rule 3.19A.3 and Section 205G of the Corporations Act, and are designed to give shareholders a clear, contemporaneous record of directors' securities interests at the time they leave the Board. This kind of disclosure is part of the broader governance scaffolding that ensures transparency around insider holdings, related-party arrangements and the overall composition of a listed company's Board.

For Arovella shareholders, the lodgement of four notices on a single day marked a notable transition point in the Company's corporate evolution. Significant Board changes, particularly when concentrated within a tight time window, often coincide with structural strategic shifts, governance reviews, Capital activity, or alignment with new investor cohorts. The Appendix 3Z notices themselves did not explain the underlying reasons for the departures, but they provided an authoritative reference point for the resulting governance changes.

The Company has now followed those governance disclosures with a more operationally focused update, confirming Dr Nicole Van Der Weerden as Acting CEO effective 7 May 2026. In announcing the appointment, Arovella highlighted her experience in biotechnology leadership, clinical development and strategic execution, while also reinforcing its intention to progress toward the Phase I trial of lead CAR-iNKT therapy candidate ALA-101. The appointment gives investors greater visibility around near-term management continuity during a period of significant Board transition.

Departing Directors and Disclosed Interests

The Appendix 3Z notices cover four directors. Andrew Nash, whose date of last notice was 12 November 2025, ceased to be a director on 4 May 2026. Debora Barton, whose date of last notice was 13 November 2025, also ceased to be a director on 4 May 2026. Michael Baker and Michael Steven Perry similarly ceased to be directors on 4 May 2026, with relevant disclosed interests including ALAAA unlisted options. The disclosures cover the directors' relevant interests as registered holders, their interests in securities not registered in their own names (including via director-related entities), and any interests in contracts.

Specific holdings disclosed include ALAAA unlisted options held by certain of the departing directors, with one notice referencing 3,372,000 ALAAA unlisted options and another referencing a director-related entity holding 5,668,280 ALAAA unlisted options. The notices also confirm that, in the case of certain departing directors, no securities were held in their own name as registered holder. The combined effect of the disclosures is to provide a clear public record of each departing director's notifiable interests as at the date of cessation.

Company Overview

Arovella Therapeutics Limited is an Australian clinical-stage biotechnology company focused on the development of innovative therapeutic platforms. Like many ASX-listed biotech companies, Arovella sits at the intersection of high-impact scientific innovation and the long-cycle, capital-intensive nature of clinical development. Its progress is measured in scientific milestones, regulatory engagements, Partnership announcements and trial readouts, all of which require strong, well-aligned governance to navigate.

The Company’s lead candidate, ALA-101, is an allogeneic CAR-iNKT cell therapy targeting CD19-positive cancers including lymphomas and leukaemias. Arovella has also continued advancing its broader iNKT platform and solid tumour programs, with management repeatedly emphasising the strategic importance of upcoming clinical milestones. The latest leadership update therefore arrives at a pivotal period for the Company as it moves closer to first-in-human trial activity.

For ASX-focused investors, biotech companies like Arovella typically require a board with deep expertise in clinical strategy, Capital Markets, intellectual property and commercial development. Changes in board composition are therefore particularly significant for biotech investors, who pay close attention to the experience profile of each director and how that experience aligns with the Company's pipeline strategy.

Strategic Context

Board transitions of this scale often signal a meaningful refresh of governance and strategic direction. While the Appendix 3Z notices themselves did not articulate the reasons for the departures or describe any incoming directors, the simultaneous nature of the four cessations was consistent with a broader Board reset rather than individual circumstances. Investors were expected to look toward subsequent Company announcements to understand the strategic rationale and governance trajectory, and the appointment of an Acting CEO has now become the first major follow-on disclosure in that process.

Within the broader ASX biotech sector, leadership continuity can be particularly important when companies are approaching key clinical or regulatory milestones. By appointing an internal executive already closely involved with operational and development strategy, Arovella appears focused on maintaining momentum across its clinical programs while the broader CEO search process continues.

Sector and Market Context

The Australian listed biotech sector continues to attract investor attention as one of the most innovation-rich segments of the local market. Companies in the space rely on disciplined governance, clinical execution and capital markets engagement to advance their development programs. Investor sentiment toward listed biotech can be volatile, often reflecting the binary nature of clinical milestones, the long lead times associated with regulatory approvals, and the structural capital requirements of running multi-year trial programs.

Within that context, board composition and executive stability are particularly important because they influence the Company's ability to align scientific progress with capital markets confidence. Boards with strong scientific, clinical and commercial credentials, paired with seasoned ASX governance experience, tend to provide investors with greater comfort that strategic decisions will be made with appropriate rigour. The market reaction on 7 May 2026 suggested investors viewed the Acting CEO appointment as an important stabilising step following the earlier Board exits.